Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure Post author: Post published: September 3, 2024 Post category:uncategorized MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients. You Might Also Like Study highlights the fragility of measles elimination in the United States April 24, 2026 Northwestern scientists identify key genes behind Parkinson’s development April 11, 2025 Genomic testing rates soar for Black patients with prostate cancer after introduction of precision medicine navigators October 3, 2023
Genomic testing rates soar for Black patients with prostate cancer after introduction of precision medicine navigators October 3, 2023